Over the past seven years, researchers in ORNL’s Geospatial Science and Human Security Division have mapped and characterized all structures within the United States and its territories to aid FEMA in its response to disasters. This dataset provides a consistent, nationwide accounting of the buildings where people reside and work.
Researchers at ORNL explored radium’s chemistry to advance cancer treatments using ionizing radiation.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
More than 50 current employees and recent retirees from ORNL received Department of Energy Secretary’s Honor Awards from Secretary Jennifer Granholm in January as part of project teams spanning the national laboratory system. The annual awards recognized 21 teams and three individuals for service and contributions to DOE’s mission and to the benefit of the nation.
Three ORNL scientists have been elected fellows of the American Association for the Advancement of Science, or AAAS, the world’s largest general scientific society and publisher of the Science family of journals.
In experiment after experiment, the synthetic radioisotope actinium-225 has shown promise for targeting and attacking certain types of cancer cells.
A team of collaborators from ORNL, Google Inc., Snowflake Inc. and Ververica GmbH has tested a computing concept that could help speed up real-time processing of data that stream on mobile and other electronic devices.
Oak Ridge National Laboratory researchers have created a technology that more realistically emulates user activities to improve cyber testbeds and ultimately prevent cyberattacks.
An Oak Ridge National Laboratory researcher has invented a version of an isotope-separating device that can withstand extreme environments, including radiation and chemical solvents.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.